SIBO INFO Blog

In this video, Dr. Pimentel explains the breakthrough test, IBS-Smart, which is the first test that can diagnose Irritable Bowel Syndrome (IBS), using novel antibody testing. When positive, it also diagnoses SIBO. A SIBO breath test would then be needed to find which subtype of SIBO is present (treatments are tailored to SIBO type).

Key Discussion Points

• Revolutionary IBS Diagnosis: The introduction of specific antibodies that now allow for the diagnosis of IBS for the first time.
• Test Generations: A comparison is made between first-generation and the more robust second-generation IBS-Smart test.
• Disease Differentiation: This test is crucial for distinguishing IBS from other gastrointestinal conditions.
• Test Accuracy:
  • The pooled sensitivity for the test is 56%. The speaker clarifies that this is not considered low for diagnosing post-infection IBS, as the maximum possible sensitivity for this specific subtype is 60%.
  • The specificity is very high, characterized by the statement: "If you're positive, you got it."
• Clinical Certainty: The IBS-Smart test is presented as the only available test that can lead to "medical certainty" for IBS diagnosis.

Note: The test only diagnoses IBS and SIBO caused by food poisoning, but no other causes. It's possible to have IBS and/or SIBO from another cause and this test would be negative in that case.

Products Mentioned:

• IBS-Smart test ($25 off with code SIBOINFO25)

In this video Dr. Pimentel explains how food poisoning causes Irritable Bowel Syndrome (IBS), also called post-infectious IBS in this scenario, and Small Intestinal Bacterial Overgrowth (SIBO).

Key Discussions and Takeaways:

• The Pathological Sequence: 
  • Pathogenic bacteria secrete the toxin CDT B.
  • The immune system develops anti-vinculin antibodies.
  • This leads to a reduction in specific nerves (ICC nerves) within the gut.
  • The consequence is stasis of the gut and subsequent bacterial overgrowth.
• Statistical Impact:
  • Approximately 1 in 9 individuals, or 11%, who contract food poisoning go on to develop IBS/SIBO.
  • Modeling based on the prevalence of food poisoning suggests it could account for about two-thirds, or 60%, of all IBS cases, especially IBS-diarrhea.

Navigating prokinetics and GLP-1 Medications: Impact on Gut Motility and SIBO

Key Discussions:

• Prokinetics and GLP-1 Medications:
  • The video addresses the question of whether prokinetic agents, which help move food through the stomach and intestines, are effective or advisable for patients on GLP-1 medications.
  • GLP-1 drugs are noted to slow down gastrointestinal motility as part of their mechanism.
  • Introducing a prokinetic like Prucalopride would likely counteract the GLP-1's intended effect, potentially making it counterproductive, especially for patients investing in expensive weight-loss medication.
  • GLP-1 agonists are described as being very powerful in inhibiting motility, to the extent that prokinetics are unlikely to overcome their effect, rendering their use in this context a waste of money.
• GLP-1 and SIBO Concerns:
  • The discussion examines whether SIBO (Small Intestinal Bacterial Overgrowth) can worsen in patients taking GLP-1s.
  • The advice given is that when a patient reaches their weight loss goal, the GLP-1 can be paused for a period, at which point SIBO could be checked.
  • There can be GI symptom improvement on GLP-1s from the significant reduction in appetite, leading to decreased food intake.
  • Less food consumption generally means less fermentation, which can lead to fewer IBS symptoms.

Key Takeaways:

• Using prokinetic agents alongside GLP-1 medications may not overcome the powerful motility-inhibiting effects of GLP-1s and may be counterproductive and a financial waste.
• GLP-1 medications can lead to a reduction in IBS-like symptoms due to decreased appetite and eating, and subsequent reduced fermentation.
• If SIBO concerns arise while on a GLP-1, it is suggested to address this after pausing the GLP-1 medication, particularly once weight loss goals are met.
  
  

Products mentioned:

• GLP-1 medicines are Ozempic and Wegovy (Semaglutide)
  
• GLP-1 and GIP medicines are Mounjaro and Zepbound (Tirzepatide)
  
• Prucalopride is prescription prokinetic sold as Motegrity (US), Resolor/Resotran (Europe/Canada)

Comparing Glucose and Lactulose for Breath Testing
This video addresses the debate surrounding the use of glucose versus lactulose as substrates in SIBO breath testing, especially in relation to the microbiome and the accuracy of findings.

Key Discussions and Takeaways:

• The Central Question: Why do studies sometimes suggest glucose is better, while clinical practice often favors lactulose? The discussion aims to clarify the differences and the reasoning behind preferring lactulose.
• Lactulose: Strength in Validation and Microbiome Link:
  • The lactulose breath test is highlighted as having been validated against the microbiome in various studies, citing publications like PLOS ONE and Villanueva.
  • A key point is that the amount of lactulose administered (e.g., 10 grams) is understood to be delivered to the colon, with minimal absorption in the upper gastrointestinal tract.
  • Dr. Pimentel believes that with improved, more accurate culture-gathering techniques, lactulose aligns well with the validated "gold standard" of microbiome analysis.
• Concerns with Glucose Testing:
  • A significant concern is that glucose can be absorbed in the mouth, throat, esophagus, and stomach, meaning a variable and potentially lesser amount reaches the small bowel or colon. This absorption rate can differ greatly among individuals.
  • The rapid absorption of glucose may lead to missing a SIBO diagnosis, since there is no substrate left to be fermented by bacteria in the lower portions of small intestine.
  • There is a noted absence of research studies that directly compare the microbiome to a glucose breath test.
  • Older studies favoring glucose are questioned due to the use of less sophisticated culture-gathering techniques at the time, which may not have been the most accurate benchmark.
• Upcoming Definitive Study: The speaker mentions a new study nearing publication that is expected to definitively address which substrate is superior and for whom.
• Current Consensus and Practice:
  • The North American consensus guidelines permit the use of either glucose or lactulose.
  • While acknowledging that some research leans towards glucose being equal to or more specific than lactulose, Dr. Pimentel personally favors lactulose based on the current "hard science."
• The Evolving "Gold Standard": The reliability of older studies is contextualized by the evolution of diagnostic techniques, suggesting that the "gold standard" for microbiome culture was not always as robust as it is now.

Products Mentioned:
Order a lactulose SIBO breath test - options here

Dr. Pimentel discusses the transition phase from an elemental diet back to regular table food, and the underlying principles of gut health and microbiome recovery.

Transitioning Back to Table Food

• Start Simple: When moving from an elemental diet, begin with easy-to-digest foods like soup and sandwiches.
• Avoid Overindulgence: Refrain from immediately consuming heavy or rich meals, such as steak, potatoes, or ribs, especially from places like steakhouses or restaurants known for large portions. These can overwhelm a gut that is still recovering.
• Gradual Reintroduction: It is essential to ease back into solid food over several days to allow the digestive system to adapt.

Understanding Gut Physiology and the Elemental Diet

• Villi Atrophy: During an elemental diet, the villi in the gut lining can become shorter because they are not being used for digestion. This is compared to an arm that shrinks when immobilized in a cast.
• Body Conservation: The human body conserves resources; unused structures tend to diminish.
• Risk of Malabsorption: Reintroducing rich foods too soon after an elemental diet can lead to diarrhea because the atrophied villi are not yet capable of absorbing nutrients effectively.
• Recovery Timeline: While villi can regrow quickly, typically within three to four days, it's important to manage the transition.

Assessing Elemental Diet Effectiveness and Patient Experience

• Don't Rush Judgment: It's advised not to declare victory or failure immediately after completing an elemental diet.
• Observation Period: Patients should wait 10 to 14 days after the elemental diet concludes before assessing its true outcome, as some temporary discomfort in the stomach can occur during this period.
• Anxiety During Transition: There can be anxiety when transitioning back to eating. The advice given is to "breathe, relax, and don't overthink" this phase.

Microbiome Recovery and Research

• Restoring Balance: Once harmful "bad actors" are eliminated from the gut (e.g., through elemental diet), the normal, beneficial flora can re-establish itself.
• Gardening Analogy: This process is likened to pulling weeds from a garden; once the weeds are gone, the desired plants (like tomatoes) can grow vigorously and thrive.
• Research Process: The video touches on the often lengthy process of scientific research, development, publication, and eventual market availability of therapies, acknowledging potential patient frustration with the pace. The goal is to publish and present findings from rigorous, expensive research to inform treatments.
  
  Products mentioned:
  - mBiota Elemental Diet - $25 off code SIBO, $50 off code SIBO50 (one time use)
  - Elemental Diets for SIBO (exclusive pricing at Fullscript)